| Not Yet Recruiting | A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untre NCT07459543 | Bristol-Myers Squibb | Phase 4 |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma NCT07288203 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Withdrawn | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the NCT05717140 | Mayo Clinic | Phase 1 |
| Recruiting | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma NCT06624644 | Linnaeus Therapeutics, Inc. | Phase 2 / Phase 3 |
| Recruiting | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive L NCT06940739 | Iovance Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Un NCT06466434 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors NCT05653661 | Mayo Clinic | Phase 1 |
| Recruiting | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable NCT05896839 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients NCT06199713 | University of Wisconsin, Madison | — |
| Unknown | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment NCT06151847 | University of Kansas Medical Center | Phase 2 |
| Suspended | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 In NCT05764395 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Recruiting | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants W NCT05727904 | Iovance Biotherapeutics, Inc. | Phase 3 |
| Recruiting | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patient NCT05428007 | NYU Langone Health | Phase 2 |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Recruiting | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma NCT05628883 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults Wi NCT05309421 | Evaxion Biotech A/S | Phase 2 |
| Completed | Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations NCT05810740 | Pierre Fabre Medicament | Phase 1 |
| Recruiting | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresecta NCT05361174 | Iovance Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma NCT05303493 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 |
| Active Not Recruiting | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D1 NCT05155254 | IO Biotech | Phase 3 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma NCT04688658 | John Kirkwood | Phase 1 / Phase 2 |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma NCT04967196 | Mayo Clinic | Phase 1 |
| Unknown | Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations NCT05103891 | Pierre Fabre Medicament | Phase 1 |
| Terminated | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma NCT04527549 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients Wi NCT04526899 | BioNTech SE | Phase 2 |
| Withdrawn | Sargramostim (GM-CSF) + PD-1 NCT04703426 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma NCT04698187 | Regeneron Pharmaceuticals | Phase 2 |
| Terminated | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma NCT04695977 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Active Not Recruiting | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV NCT04462406 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Withdrawn | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma NCT04759846 | Pierre Fabre Medicament | Phase 1 |
| Completed | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma NCT04493203 | Yana Najjar | Phase 2 |
| Terminated | A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Ad NCT04625205 | BioNTech US Inc. | Phase 1 |
| Unknown | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inope NCT04521075 | Ella Therapeutics Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With M NCT04645680 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or M NCT03816332 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma NCT04337931 | Apexigen America, Inc. | Phase 2 |
| Terminated | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma NCT03865212 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Thera NCT03719131 | Emory University | Phase 2 |
| Completed | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) NCT03679767 | Incyte Corporation | Phase 2 |
| Completed | Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma NCT03501368 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02965716 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Mon NCT03430297 | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 |
| Completed | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melano NCT03033576 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery NCT03021460 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutate NCT02910700 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafe NCT02224781 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread NCT02196181 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectabl NCT02115243 | Duke University | Phase 1 |
| Active Not Recruiting | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mut NCT01989585 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707 | Mayo Clinic | Phase 1 |
| Completed | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed NCT01950390 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma NCT02158520 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer NCT01902173 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously NCT01927419 | Bristol-Myers Squibb | Phase 2 |
| Completed | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in NCT01726738 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Ipilimumab and Imatinib Mesylate in Advanced Cancer NCT01738139 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot B NCT01134614 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanom NCT01107665 | University of California, Irvine | Phase 2 |
| Available | Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release NCT05398640 | Iovance Biotherapeutics, Inc. | — |